The estimated Net Worth of Paul W. Hoelscher is at least 66.6 百万$ dollars as of 20 April 2022. Mr. Hoelscher owns over 50,000 units of Horizon Therapeutics Plc stock worth over 5,936,999$ and over the last 10 years he sold HZNP stock worth over 56,249,315$. In addition, he makes 4,443,590$ as Chief Financial Officer、 Executive Vice President at Horizon Therapeutics Plc.
Paul has made over 15 trades of the Horizon Therapeutics Plc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 50,000 units of HZNP stock worth 1,107,000$ on 20 April 2022.
The largest trade he's ever made was selling 307,045 units of Horizon Therapeutics Plc stock on 6 April 2022 worth over 33,778,020$. On average, Paul trades about 27,642 units every 27 days since 2014. As of 20 April 2022 he still owns at least 51,049 units of Horizon Therapeutics Plc stock.
You can see the complete history of Mr. Hoelscher stock trades at the bottom of the page.
Paul W. Hoelscher is Chief Financial Officer, Executive Vice President of the Company. Previously, Mr. Hoelscher was our executive vice president, finance from June 2014 through September 2014. Prior to joining Horizon, Mr. Hoelscher served as senior vice president, finance-treasury and corporate development of OfficeMax, Inc., from August 2013 to May 2014, and as vice president, finance-treasury and corporate development of OfficeMax from August 2012 to July 2013. Prior to that, Mr. Hoelscher served in various finance roles at Alberto Culver Company from 1993 to 2012 and in various positions in the audit practice at KPMG LLP from 1986 to 1993. He currently serves on the board of trustees of the Illinois Chapter of the Leukemia and Lymphoma Society. Mr. Hoelscher received his bachelor of science degree in accountancy from the University of Illinois at Urbana-Champaign and is a certified public accountant.
As the Chief Financial Officer、 Executive Vice President of Horizon Therapeutics Plc, the total compensation of Paul Hoelscher at Horizon Therapeutics Plc is 4,443,590$. There are 3 executives at Horizon Therapeutics Plc getting paid more, with Timothy Walbert having the highest compensation of 13,873,200$.
Paul Hoelscher is 55, he's been the Chief Financial Officer、 Executive Vice President of Horizon Therapeutics Plc since 2014. There are 10 older and 12 younger executives at Horizon Therapeutics Plc. The oldest executive at Horizon Therapeutics Plc is William Daniel, 67, who is the Independent Director.
Paul's mailing address filed with the SEC is C/O HORIZON THERAPEUTICS PLC,, 70 ST. STEPHEN?S GREEN, DUBLIN, L2, D02 E2X4.
Over the last 13 years, insiders at Horizon Therapeutics Plc have traded over 454,905,275$ worth of Horizon Therapeutics Plc stock and bought 11,809,010 units worth 58,823,653$ . The most active insiders traders include Jeff Himawan、Woodlands Health Ventures F...、Jean Francois Formela. On average, Horizon Therapeutics Plc executives and independent directors trade stock every 13 days with the average trade being worth of 12,248,018$. The most recent stock trade was executed by Gino Santini on 2 October 2023, trading 23,092 units of HZNP stock currently worth 351,691$.
at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.
Horizon Therapeutics Plc executives and other stock owners filed with the SEC include: